{"id":"predinsone-prednisolone","safety":{"commonSideEffects":[{"rate":"10-30","effect":"Hyperglycemia / glucose intolerance"},{"rate":"5-20","effect":"Hypertension"},{"rate":"varies with duration","effect":"Osteoporosis / bone loss"},{"rate":"5-15","effect":"Infections (opportunistic)"},{"rate":"5-10","effect":"Insomnia / mood changes"},{"rate":"5-15","effect":"Gastrointestinal upset"},{"rate":"varies","effect":"Cushingoid features (with chronic use)"},{"rate":"dose-dependent","effect":"Immunosuppression"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"These synthetic glucocorticoids mimic cortisol and bind to intracellular glucocorticoid receptors, translocating to the nucleus to modulate gene expression. This results in broad immunosuppression, reduced production of inflammatory mediators (cytokines, chemokines, adhesion molecules), and decreased immune cell proliferation and migration. They are used across multiple therapeutic areas for their potent anti-inflammatory and immunosuppressive effects.","oneSentence":"Prednisone/prednisolone is a corticosteroid that suppresses the immune system and reduces inflammation by binding to glucocorticoid receptors and inhibiting pro-inflammatory cytokine production.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:29:57.204Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Inflammatory and autoimmune disorders (rheumatoid arthritis, lupus, vasculitis)"},{"name":"Hematologic malignancies (as adjunctive therapy in lymphomas and leukemias)"},{"name":"Allergic and respiratory conditions (asthma, COPD exacerbations)"},{"name":"Adrenal insufficiency and other endocrine disorders"}]},"trialDetails":[{"nctId":"NCT06764485","phase":"PHASE3","title":"A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer","status":"RECRUITING","sponsor":"Celgene","startDate":"2025-03-13","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":960}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Predinsone/Prednisolone","genericName":"Predinsone/Prednisolone","companyName":"Celgene","companyId":"celgene","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Prednisone/Prednisolone is a small molecule glucocorticoid receptor agonist, classified as an AGONIST. It is used to treat various conditions, including metastatic castration-resistant prostate cancer, as per clinical trials registered on ClinicalTrials.gov.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}